Solit DB - Search Results

1

Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol.

Solit DB, Basso AD, Olshen AB, Scher HI, Rosen N. Solit DB, et al. Cancer Res. 2003 May 1;63(9):2139-44. Cancer Res. 2003. PMID: 12727831

2

Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-2158, 2001.

Münster PN, Basso A, Solit D, Norton L, Rosen N. Münster PN, et al. Clin Cancer Res. 2001 Aug;7(8):2228-36. Clin Cancer Res. 2001. PMID: 11489796

3

Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2.

Basso AD, Solit DB, Munster PN, Rosen N. Basso AD, et al. Among authors: solit db. Oncogene. 2002 Feb 14;21(8):1159-66. doi: 10.1038/sj.onc.1205184. Oncogene. 2002. PMID: 11850835 Free PMC article.

4

17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.

Solit DB, Zheng FF, Drobnjak M, Münster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus DB, Scher HI, Rosen N. Solit DB, et al. Clin Cancer Res. 2002 May;8(5):986-93. Clin Cancer Res. 2002. PMID: 12006510

5

Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function.

Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P, Rosen N. Basso AD, et al. Among authors: solit db. J Biol Chem. 2002 Oct 18;277(42):39858-66. doi: 10.1074/jbc.M206322200. Epub 2002 Aug 9. J Biol Chem. 2002. PMID: 12176997 Free article.

6

Total synthesis as a resource in the discovery of potentially valuable antitumor agents: cycloproparadicicol.

Yamamoto K, Garbaccio RM, Stachel SJ, Solit DB, Chiosis G, Rosen N, Danishefsky SJ. Yamamoto K, et al. Among authors: solit db. Angew Chem Int Ed Engl. 2003 Mar 17;42(11):1280-4. doi: 10.1002/anie.200390329. Angew Chem Int Ed Engl. 2003. PMID: 12645064 No abstract available.

7

Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration.

Smaletz O, Galsky M, Scher HI, DeLaCruz A, Slovin SF, Morris MJ, Solit DB, Davar U, Schwartz L, Kelly WK. Smaletz O, et al. Among authors: solit db. Ann Oncol. 2003 Oct;14(10):1518-24. doi: 10.1093/annonc/mdg415. Ann Oncol. 2003. PMID: 14504052 Free article. Clinical Trial.

8

Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors.

de Candia P, Solit DB, Giri D, Brogi E, Siegel PM, Olshen AB, Muller WJ, Rosen N, Benezra R. de Candia P, et al. Among authors: solit db. Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12337-42. doi: 10.1073/pnas.2031337100. Epub 2003 Oct 2. Proc Natl Acad Sci U S A. 2003. PMID: 14526102 Free PMC article.

9

Development of purine-scaffold small molecule inhibitors of Hsp90.

Chiosis G, Lucas B, Huezo H, Solit D, Basso A, Rosen N. Chiosis G, et al. Curr Cancer Drug Targets. 2003 Oct;3(5):371-6. doi: 10.2174/1568009033481778. Curr Cancer Drug Targets. 2003. PMID: 14529388 Review.

10

Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.

She QB, Solit D, Basso A, Moasser MM. She QB, et al. Clin Cancer Res. 2003 Oct 1;9(12):4340-6. Clin Cancer Res. 2003. PMID: 14555504

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

389 results

Search Page

Filters